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A cost-of-illness analysis of β-Thalassaemia
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from a tertiary level teaching hospital
Hamish Reed-Embleton1, Savinda Arambepola2, Simon Dixon1, Behrouz Nezafat Maldonado3,
Anuja Premawardhena4,5* , Mahinda Arambepola6, Jahangir A. M. Khan3 and Stephen Allen3
Abstract
Background: Sri Lanka has a high prevalence of β-thalassaemia major. Clinical management is complex and long-
term and includes regular blood transfusion and iron chelation therapy. The economic burden of β-thalassaemia for
the Sri Lankan healthcare system and households is currently unknown.
Methods: A prevalence-based, cost-of-illness study was conducted on the Thalassaemia Unit, Department of
Paediatrics, Kandy Teaching Hospital, Sri Lanka. Data were collected from clinical records, consultations with the
head of the blood bank and a consultant paediatrician directly involved with the care of patients, alongside
structured interviews with families to gather data on the personal costs incurred such as those for travel.
Results: Thirty-four children aged 2–17 years with transfusion dependent thalassaemia major and their parent/
guardian were included in the study. The total average cost per patient year to the hospital was $US 2601 of which
$US 2092 were direct costs and $US 509 were overhead costs. Mean household expenditure was $US 206 per year
with food and transport per transfusion ($US 7.57 and $US 4.26 respectively) being the highest cost items. Nine
(26.5%) families experienced catastrophic levels of healthcare expenditure (> 10% of income) in the care of their
affected child. The poorest households were the most likely to experience such levels of expenditure.
Conclusions: β-thalassaemia major poses a significant economic burden on health services and the families of
affected children in Sri Lanka. Greater support is needed for the high proportion of families that suffer catastrophic
out-of-pocket costs.
Keywords: Children, Cost-of-illness, Sri Lanka, Thalassaemia
Background
β-thalassaemia major is Sri Lanka’s most common serious
single gene disorder with an estimated prevalence of 2.2%
[1, 2]. Medical advances in recent decades have trans-
formed this inherited haemoglobinopathy from a severe,
life-limiting disease to a treatable chronic condition. With
high quality of care, patients can expect a near-normal life
as fully integrated, industrious members of society [2].
The lifelong treatment regime for β-thalassaemia major
comprises regular (usually monthly) blood transfusion and
iron chelation therapy (ICT) [3]. However, despite ICT,
transfusional iron overload causes many complications
affecting organ systems such as the liver, endocrine organs
and heart. Cardiac complications, including pericarditis
and dilated cardiomyopathy, still represent 71% of the
cause of death in thalassaemic patients [2]. Regular clinic
appointments are used to screen for complications
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including the use specialist equipment such as ultrasound,
slit-lamps, audiograms and blood glucose monitoring
devices. Blood tests also include serological testing for
HIV and hepatitis viruses. The screening and clinical
management of these complications requires a specia-
lised multidisciplinary team approach. During hospital
care, associated health-care costs include non-medical
personnel, staff transport, supplies and requisites, main-
tenance, electricity, water, food, contractual services
and other recurrent expenditure.
Cost-of-illness (COI) studies aim to measure the total
societal costs of a disease. Total societal costs extend
beyond those related to health care to include household
expenditures, and in some studies, lost productivity
associated with employment. An important concept
related to COI studies is the “cost burden” of a disease,
which refers to household cost expressed as a percentage
of household income. A common approach to measur-
ing economic hardship associated with health payments
is to define a ‘catastrophic’ spending level of > 10% of
household income. This degree of cost burden is consid-
ered to directly impact consumption of basic needs such
as food and education or trigger the sales of assets lead-
ing to higher levels of debt or poverty [4–8].
We identified 14 COI studies of thalassaemia, pub-
lished between 1975 and 2017, in Canada, India, Iran,
Israel, Italy, Myanmar, Taiwan, Thailand and the UK
[1, 7–19]. Reported medical costs to health services
ranged from $US 873 to almost $40,000 per patient
year [9, 13]. In Sri Lanka, the national blood transfusion
service is provided by the Ministry of Health and com-
prises 98 hospital-based blood banks and there are two
standalone thalassaemia centres. De Silva et al. esti-
mated in 2000 that the cost of preparing blood, ICT,
essential investigations and hospital visits was LKR 175,
000 (equivalent to $US 2465) [3]. This estimate is now
outdated in view of substantial changes to patient care.
The costs of thalassaemia do not just fall on the
health service but also on the affected individual and
their household as treatment decisions and coping
mechanisms usually occur at the household level [20].
Seven of the economic analyses assessed costs to the
household [1, 7, 9, 11, 16, 18, 19] but none assessed the
cost burden. No assessment of the costs to families was
undertaken in the study in Sri Lanka [3]. We undertook
a prevalence based, cost-of-illness study to provide an
updated estimate of the economic burden to both the
health service and families of transfusion dependent β-
thalassaemia in children in Sri Lanka. Health service
costs include both direct hospital costs, which are
directly related to patient care such as staff costs, and
indirect hospital costs, such as overheads. Household
costs include items such as travel and food costs when
attending treatment centers.
Methods
Study location
This study was undertaken in Kandy Teaching Hospital
(KTH) in the Central province of Sri Lanka. KTH, the
second largest medical institution in the country, has
two main paediatric wards with a capacity of 100 beds
and a single integrated 8 bedded blood transfusion unit.
As well as patients living in the hospital catchment area,
many patients from adjoining districts attend for specia-
lised medical care such as thalassaemia management. In
2017 there was over 22,000 admissions to KTH includ-
ing almost 8000 paediatric cases [21].
Patients
The inclusion criteria were children (< 18 years) with a
diagnosis of β-thalassaemia major who had attended KTH
for at least 1 year. All children who attended for blood
transfusion during the period of 12th June – 11th of July
2017 were invited to take part in the study. In order to
estimate the mean cost of the patients and assuming a
normal distribution, we aimed to recruit at least 30 cases
as directed by the Central Limit Theorem [22].
Collection of demographic and clinical data
At the time of blood transfusion, demographic data and
the number of transfusions and units of blood received,
investigations and drug treatment over the preceding 12
months was extracted from case records.
Estimating health service costs
Costs were estimated for both in-patient care and attend-
ing out-patient clinics. Staff costs per inpatient day were
calculated using estimates of workload intensity [23]. Staff
costs were allocated to individual patients based on the
complexity of their care needs categorised according to a
four point scale, with each category representing a meas-
ure of workload intensity (Table 1). Patients were allo-
cated to the scale by the doctors working on the relevant
wards.
A breakdown of monthly overhead spending for the
hospital was provided by the accounting staff. Direct
Table 1 Workload unit scoring system
Definition Patient score Relative
workload
intensity
Patients who require less than average
care E.g. Regular transfusion visits
1 1
Sub-acute patients who require the
standard level of care
2 2.5
Acute patients who require more than
average care
3 3.5
Intensive care patients who require a
high level of care
4 7
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hospital costs were then inflated to take into account the
indirect costs of care using the mark-up method [24].
With this method, the ratio of indirect to direct costs is
calculated based on available budget information, then
used to adjust the direct costs associated with the patient
population of interest (and for which indirect cost infor-
mation is not available) providing an estimate of the
total hospital cost (direct + indirect).
The equipment used for monitoring for complications
was not exclusively used in the care of thalassaemic pa-
tients; therefore, we estimated the cost per test of using
such equipment. The price of equipment along with its
estimated life expectancy was used to calculate the
equipment cost per test. The cost per month of equip-
ment (mE) was calculated using the formula mE ¼ cE
L
,
where cE is the purchase price of equipment and L is the
life expectancy in months. The cost per test (C) was calcu-
lated using the formula C ¼ mEþsW
n
, where sW is the
monthly staff wages required to run the clinic and n is the
total number of tests performed in 1month. Table 2 sum-
marises the resource consumption and measurement.
Estimating household costs
Structured interviews were conducted with children and
their parents/guardians in the local language by a trained
research assistant (see interview guide in Additional file 1).
We expressed household health expenditure per month as
a percentage of total monthly household income [25–28].
Statistical analysis
Descriptive statistics were used to summarise the partici-
pants and cost items. Mean (SD) was used for normally
distributed data and median (IQR) for non-normal data.
A Pearson correlation test was used for analysis and P-
value < 0.05 for statistical significance.
Results
All participants who were invited to join the study
agreed to take part and a total of 34 children attend-
ing for blood transfusion were enrolled. Median age
was 10.0 years (range 2.3–17.0 years) and 22 (64.7%)
were female. Median (range) age at first transfusion
was 4 [1–11, 29, 30] months (age not available for
one child).
Direct hospital costs
Blood transfusion and ICT
Median (range) number of transfusion sessions per year
was 12.0 (11.0–14.0) and the median (IQR) number
units of units transfused per year was 21.0 (18.5–23.0).
The cost of preparing 1 unit of blood was $US 44 (per-
sonal communication; Head of the Blood Bank, KTH)
resulting in an average cost of $US 893 per patient year
for blood transfusions.
26 (76.5%) patients received oral deferasirox, 1 (2.9%)
IV deferoxamine and 7 (20.1%) combined ICT including
transition from oral to IV treatment. During the 12
months studied, 27 patients remained on a stable dose
of ICT whilst 7 patients changed either their dose or
ICT agent at least once. The cost of oral deferasirox 100
mg and 400 mg was $US 0.61 and $US 1.34 respectively
and IV deferoxamine 500 mg cost $US 3.04. On average,
ICT cost was mean (SD) $US 967.3 (651.7) per patient
year. The average cost of concomitant medication was
mean (SD) $US 5.10 (7.2) per patient year. ICT
accounted for 99.5% of the total drug costs.
Table 2 Summary of resource consumption
Resource Measure Source of data Valuation
Blood transfusion
- Staff Time spent Accounting department Salary
- Transfusion consumables Number and types of transfusion Patient records
Pharmacy department
Blood bank
Price per item
Drug therapy
- ICT Dose and frequency Patient records Price per item
- Concomitant medication Pharmacy department
Clinic and outpatient
- Staff Number of type Patient records Salary
- Equipment Clinician interviews Cost per test
Overheads Number of items of shared services Accounting department Price per item
Household costs
- Transport and food Expenditure per visit Structured interviews Self-reported
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Staff
The paediatric team was composed of 1 Consultant, 1
Senior Registrar, 3 Registrars, 4 Senior House Officers, 4
House Officers, 1 Sister and 17 Nurses. The combined
monthly salary of these staff was $US 14,126. The total
workload units were 107 which gives a staff cost of $US
4.34 per workload unit. Patients remained on the ward
for a mean (SD) of 2.1 (0.54) days per admission and this
amounts to an average staff cost of $US 114 per patient
year.
Investigations and clinic visits
The number of investigations, costs per unit and cost
per patient year of each investigation were combined
with clinic attendance costs; totalling $US 3832 equiva-
lent to $US 113 per patient year.
Age positively correlated with treatment cost (p-value<
0.001) (Fig. 1) reflecting the increased transfusion and ICT
requirements in older children with an increase of $US 112
for every 1 year increase in age.
Indirect hospital costs
Overhead and building
The total indirect costs were $US 389,510 and the total
direct costs borne by the hospital were $US 1,600,910
giving a mark-up percentage of 24.3%. This equates to
an additional $US 509 per patient year in overhead
costs.
Household costs
In 31 (91.2%) children, the mother provided informa-
tion, the grandmother in 2 (5.8%) and the father in 1
(2.9%). The highest educational level for household
head was primary for 6 (17.6%), secondary for 24
(70.6%) and graduate for 3 (8.8%; not reported for 1
child). Four (11.8%) of the respondents were self-
employed, 1 (2.9%) was employed and 29 (85.3%) re-
ported housework as their occupation.
Total household costs were $US 206 per year with
food and transport ($US 99 and $US 51 respectively)
being the highest cost items. Two patients reported
hospitalisation in the past 12 months; 1 for 15 days and
1 for 4 days with a household cost of $US 164 and $US
3 respectively which was included in the household
costs. The other cost items measured can be found in
the supplementary file. Eight children were too young to
attend school and the remaining 26 reported median
(range) of 37.5 (24–84) days of absence from school per
year.
Household cost burden
Mean (SD) household annual income was $US 2548
(1340). One household reported no income being
dependent on bank loans and was excluded from the
cost burden calculations as their income denominator
was 0. Figure 2 shows that cost burden varied between
income quartiles. Only 1 household had a low-cost bur-
den and 9/33 (27.3%) experienced a catastrophic cost
burden despite the free medical care available in Sri
Lanka. Households in the lowest income quartile experi-
enced a median cost burden of over 10% which is often
regarded as ‘catastrophic’ [4–6]. Of households in the
lowest income quartile, cost burdens were either high
(N = 2) or catastrophic (N = 5).
In total 5 families took out a loan to help cover the
costs generated by their child’s thalassaemia. Of these 4
out of 5 were in the lowest income quartile (one was in
the second highest).
Total costs
The total annual direct hospital cost was $US 2092 per
patient year. This figure was inflated accordingly by the
mark up of 24%, which amounts to $US 2601 per patient
year. Household costs were $US 206. This amounts to a
total societal burden of $US 2807 per patient year.
Figure 3 reports the breakdown of total societal cost
Fig. 1 Relationship between age and direct hospital costs. y = 112.07x + 1060.8 R2 = 0.3748. Pearsons correlation co-efficient = 0.64
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expressed as a percentage. As shown BT-ICT makes up
the 66% of the total cost.
Discussion
This cost-of-illness study of transfusion dependent β-
thalassaemia major in children in Sri Lanka includes a
comprehensive assessment of direct and indirect costs to
the healthcare system and costs to household budgets.
We estimated that the healthcare costs of managing
thalassaemia are approximately $US 2601 per patient
year. In addition, despite free healthcare in Sri Lanka,
households frequently spend over 10% of their annual
income on blood transfusion sessions, follow up tests,
special foods and hospitalisation; with those most likely
to spend this ‘catastrophic’ level being from the lowest
income quartile.
The only previous economic analysis in Sri Lanka,
published in 2000, estimated an annual cost of treating
thalassaemia of LKR 175,000 ($US 2465) per patient year
[3]. When inflated by the consumer price index provided
by the World Bank [31] this value is $US 10,649 at
present day value. One potential cause for this lower
cost is in the change in the drug of choice for ICT from
a sub-cutaneous infusion of deferoxamine to oral defera-
sirox. Deferasirox is considerably cheaper than IV defer-
oxamine at current pharmacy prices (500mg = $US 1.96
vs 3.06; costs provided by the pharmacy department)
and does not require an infusion pump for administra-
tion. Other advances in medical care likely also contrib-
ute to this lower estimate. The International Diabetes
Federation (IDF) estimated the cost of managing dia-
betes in Sri Lanka at $US 185 per patient year in 2017
[32]. This means we estimate the annual direct hospital
cost of thalassaemia in children ($US 2092) to be over
10 times that of an adult diabetic patient.
Factors accounting for the variation in costs in previ-
ous studies [1, 7–19] included age of the patients, treat-
ment regimen and the number of complications.
Differences in study design included the use of hypo-
thetical patients and which costs were included such as
productivity loss and those related to complications.
Costs varied considerably between studies conducted in
the same country. For example In Iran, the cost per
patient year ranged from $1730 to $8321 [18, 19]. This
highlights the disparities in methods of cost assessment
including the use of assumptions related to treatment
patterns, patient sample, overhead allocation method,
local unit costs and data collection methods; all of these
factors limit the scope for inter study comparison. The
use of a standard set of reporting guidelines as recom-
mended for cost-effectiveness studies [33] would ensure
that studies capture similar costs and enable better
inter-study comparison.
The true economic impact of a disease must con-
sider factors beyond health related expenditures, such
as family coping strategies and impact on future live-
lihood [20]. In severe poverty, where a household
struggles to achieve minimum food or fuel levels,
even a small change (e.g. the loss of 1 day’s wage)
may have substantial implications for the wellbeing of
the whole household requiring drastic coping strat-
egies [4]. Family strategies often aim to maintain
short-term economic sustainability for the household
[34] but the selling of assets or borrowing of money
to help with treatment clearly generate future chal-
lenges and costs. The relatively low levels of house-
hold income in our study resulted in about 1 in 4
households experiencing catastrophic costs (> 10% of
total income). Of the 5 families who took out a loan
to help cover the costs of thalassaemia, 4 were from
Fig. 2 Relationship between income quartile and cost burden. Boxes
show Median and IQR, whiskers show range
Fig. 3 Total societal cost. Values are reported in $US and expressed
as a percentage of the total societal cost
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family or neighbours exemplifying the bonding /
bridging forms of social capital, and the greater need
for the poorest families to utilise family networks and
assets compared to families with more resources [35].
To further understand the complex dynamics of house-
hold expenditure on healthcare and the impact of lost
schooling for individuals, longitudinal in-depth quantita-
tive and qualitative research that assesses expenditure and
future income implications is needed. A greater under-
standing of coping methods and how assets are mobilised
is necessary to assess the impact on household livelihoods.
We found out-of-pocket costs were not associated with
household income (Pearson coefficient 0.21, p-value 0.20).
Since the out-of-pocket payments contained mainly trans-
port and food costs, the observed correlation was not un-
expected. Our results indicate that there are discrepancies
between household cost burden across income quartiles,
despite the free medical care available in Sri Lanka. How-
ever, we were unable to adequately investigate spending
patterns and no data were collected on household’s ability
to pay for basic needs after the cost of healthcare had been
taken out. Studies that explore how households prioritise
expenditure, how they perceive basic needs, and the fac-
tors which underpin inequality and financial protection
would help generate a more complete picture.
Strengths and limitations
The study estimated the costs of managing β-thalassaemia
major both for health services and households. We
recruited children of diverse ages, socioeconomic back-
grounds and healthcare requirements to provide a broad
view of costs to households. However, the data relate only
to children in one specific healthcare setting; conducting
the study in more than one hospital site and recruiting a
greater sample size, would improve validity and generalis-
ability especially as distance from treatment facilities and,
therefore, transport costs may differ amongst regions. This
additional information would be important when consid-
ering policy implications at the national level. In 2016, the
median income in Kandy was 42000Rs compared with a
national median of 44000Rs as reported by the Depart-
ment of Census and Statistics [36]. Kandy was the 4th
richest of 25 districts in this census data with the national
median somewhat skewed by Colombo which has a
median of 70,000Rs. Therefore, we consider that the eco-
nomic status of the Kandy population is approximately
representative of the national population outside of
Colombo.
When calculating the mark-up percentage, sufficient
data were not available to determine whether certain
cost centres were utilised by the patients in our study.
The high cost of medication for ICT is unlikely to have
a linear correlation with overhead costs as assumed
when using the marginal mark-up methodology. This
means the mark-up percentage may be an over-estimate
of the actual value. On the other hand, the cost of
administrative, domestic and pharmacy staff were not in-
cluded in the overall staff cost. A study of administrative
costs in 8 nations reported administrative costs make up
between 12 and 25% of total hospital costs [37].
In this study, costs were only estimated over a one-year
period. Longer periods of observation are needed to get a
more accurate view of costs and to quantify the long-term
consequences of thalassaemia. This is of particular import-
ance in thalassaemia due to the increasing cost with age as
demonstrated in other studies. Using an incidence-based
approach (which includes costs throughout a patient’s life-
time) would be more useful in policy decision making
where preventative measures are considered as it provides a
more accurate level of saving. Also, incidence-based studies
allow an analysis of the disease throughout the life-course
allowing researchers to develop improved clinical and
therapeutic guidelines for disease management.
Finally, we did not attempt to estimate the cost of the
potential impact that loss of education could have on
future financial capabilities and acquisition of household
human capital [38]. A study comparing adult employ-
ment and income in people with β-thalassaemia and
those without would be required. This could then be
applied to the number of adults with β-thalassaemia in a
prevalence-based COI study.
Conclusion
Managing thalassaemia cost the healthcare system in Sri
Lanka an estimated $US 2601 per patient year. Most of
this total cost can be attributed to blood transfusion and
ICT. Despite free healthcare, many households incurred
catastrophic costs. Many families caring for a child with
β-thalassaemia require financial support to mitigate ad-
verse financial hardship.
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